PMV Pharmaceuticals, Inc. (PMVP) — Financial statements
Income statement, balance sheet, and cash flow for PMV Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 1↓9.0% | 1↑93.4% | 0.65↓49.3% | 1 | |
| Gross Profit | 0.00↑100.0% | -1↑9.0% | -1↓93.4% | -0.65↑49.3% | -1 | |
| Operating Expenses | ||||||
| R&D Expenses | 70↑21.8% | 57↑5.0% | 55↑5.7% | 52↑42.8% | 36 | |
| General & Administrative Expenses | 16 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 16↓39.3% | 27↑11.0% | 24↓1.9% | 25↑18.7% | 21 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 86↑2.3% | 84↑6.9% | 79↑3.3% | 76↑34.0% | 57 | |
| Total Costs & Expenses | 86↑0.9% | 85↑6.6% | 80↑4.0% | 77↑32.2% | 58 | |
| Operating Results | ||||||
| Operating Income | -86↓0.9% | -85↓6.6% | -80↓4.0% | -77↓32.2% | -58 | |
| Depreciation & Amortization | 0.13↓88.4% | 1↓9.0% | 1↑93.4% | 0.65↓49.3% | 1 | |
| EBITDA | -86↓16.8% | -74↓8.8% | -68↑6.8% | -73↓28.5% | -57 | |
| EBIT | -86↓15.2% | -75↓8.5% | -69↑6.0% | -73↓26.8% | -58 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↓40.5% | 11↓4.6% | 11↑208.0% | 4↑707.8% | 0.45 | |
| Interest Income | 6↓40.5% | 11↓4.6% | 11↑208.0% | 4↑707.8% | 0.45 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -11↑4.8% | -11↓200.9% | -4↓690.2% | -0.47 | |
| Other Income / Expenses | 6↓40.9% | 11↓4.8% | 11↑200.9% | 4↑690.2% | 0.47 | |
| Income Before Tax | -80↓6.8% | -75↓8.5% | -69↑6.0% | -73↓26.8% | -58 | |
| Income Tax Expense | -2↑86.5% | -16↓805100.0% | 0.00↑122.2% | -0.01↓139.1% | 0.02 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -78↓32.4% | -59↑14.9% | -69↑5.9% | -73↓26.7% | -58 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -78↓32.4% | -59↑14.9% | -69↑5.9% | -73↓26.7% | -58 | |
| Bottom-Line Net Income | -78↓32.4% | -59↑14.9% | -69↑5.9% | -73↓26.7% | -58 | |
| EPS (Basic) | -1.48↓30.0% | -1.14↑21.0% | -1.44↑10.6% | -1.61↓25.8% | -1.28 | |
| EPS (Diluted) | -1.48↓30.0% | -1.14↑21.0% | -1.44↑10.6% | -1.61↓25.8% | -1.28 | |
| Weighted Average Shares | 53↑1.9% | 52↑7.4% | 48↑5.3% | 46↑1.0% | 45 | |
| Weighted Average Diluted Shares | 53↑1.9% | 52↑7.4% | 48↑5.3% | 46↑1.0% | 45 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.